Page last updated: 2024-12-06

3-(cyclohexylamino)-1-propanesulfonic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID70815
CHEBI ID191088
SCHEMBL ID37872
SCHEMBL ID4441928
MeSH IDM0255781

Synonyms (51)

Synonym
n-cyclohexyl-3-aminopropanesulfonic acid
cxs ,
3-cyclohexyl-1-propylsulfonic acid
einecs 214-492-1
brn 2835588
1-propanesulfonic acid, 3-(cyclohexylamino)-
caps, >=98.0%
caps, bioxtra, >=98.0%
3-(cyclohexylamino)propanesulfonic acid
CAPS ,
3-(cyclohexylamino)-1-propanesulfonic acid
DB02219
3-cyclohexylaminopropane-1-sulphonic acid
C-9227
caps, bioultra, >=99.0% (tlc)
3-cyclohexylaminopropanesulfonic acid
1135-40-6
3-(cyclohexylamino)propane-1-sulfonic acid
CHEBI:191088
3-(cyclohexylamino)propane-1-sulonic acid
cyclohexylaminopropanesulfonic acid
ammonia; cyclohexane; hydrogen sulfite; propane
A803066
M01457
unii-4w981o1lxp
4w981o1lxp ,
c9h19no3s
FT-0615569
AKOS015897412
SCHEMBL37872
was-12
caps [mi]
SCHEMBL4441928
DTXSID3061554
1219804-15-5
3-(cyclohexylamino)-1-propanesulfonic-d17 acid
mfcd00003837
caps, anhydrous, free-flowing, redi-dri(tm), >=98.0%
caps, vetec(tm) reagent grade, >=98%
Q5008765
3-(cyclohexylamino)-propane sulfonic acid (caps)
F20300
CS-0015179
DS-13823
3-(cyclohexylamino)propane sulfonic acid
caps (3-(cyclohexylamino)propanesulphonic acid)
caps (3-(cyclohexylamino)propanesulfonic acid)
caps-3-cyclohexylamino-propanesulphonic-acid
buffer caps high-purity grade 1kg
3-cyclohexylaminopropanesulfonicacid
HY-D0869
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amineA compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (14.29)18.2507
2000's5 (71.43)29.6817
2010's1 (14.29)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.55 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index5.04 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]